Workflow
中国医药(600056) - 2025 Q1 - 季度财报
China MehecoChina Meheco(SH:600056)2025-04-29 11:40

Financial Performance - The company's operating revenue for Q1 2025 was ¥8,262,744,582.75, a decrease of 5.84% compared to ¥8,774,845,924.57 in the same period last year[4] - Net profit attributable to shareholders was ¥166,379,236.02, representing an increase of 14.27% from ¥145,599,951.99 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥161,389,244.66, up 14.70% from ¥140,701,002.65 in the previous year[5] - The basic and diluted earnings per share were both ¥0.1112, reflecting a growth of 14.29% compared to ¥0.0973 in the same period last year[5] - The company reported a net profit margin improvement, with net profit for Q1 2025 showing signs of recovery compared to the previous quarter[20] - The net profit for Q1 2025 was ¥227,200,028.63, compared to ¥202,880,820.28 in Q1 2024, reflecting an increase of about 12.0%[22] - The total profit for Q1 2025 was ¥304,613,642.69, up from ¥273,566,147.94 in Q1 2024, indicating a growth of approximately 11.3%[21] - The operating profit for Q1 2025 was ¥304,650,879.12, compared to ¥275,532,249.93 in Q1 2024, marking an increase of around 10.5%[21] - The total comprehensive income for Q1 2025 was ¥228,085,005.92, compared to ¥204,242,302.70 in Q1 2024, showing an increase of about 11.7%[22] Assets and Liabilities - The total assets increased by 1.16% to ¥35,691,055,852.05 from ¥35,281,058,913.54 at the end of the previous year[5] - Total liabilities increased to CNY 21,351,740,582.17 as of March 31, 2025, compared to CNY 21,170,228,649.58 at the end of 2024[17] - Non-current liabilities rose to CNY 4,127,982,443.79 as of March 31, 2025, from CNY 3,993,465,112.13 at the end of 2024[17] - Cash and cash equivalents decreased to CNY 2,769,756,319.52 as of March 31, 2025, from CNY 4,214,785,882.65 at the end of 2024[15] - Accounts receivable increased to CNY 14,304,068,583.00 as of March 31, 2025, compared to CNY 12,750,985,655.25 at the end of 2024, reflecting a 12.1% rise[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 146,543[10] - The largest shareholder, China General Technology (Group) Holding Limited, holds 31.92% of the shares, totaling 477,424,181 shares[10] Cash Flow - The net cash flow from operating activities was negative at -¥1,481,576,242.42, compared to -¥1,206,669,907.55 in the same period last year[5] - The cash flow from operating activities for Q1 2025 was -¥1,481,576,242.42, worsening from -¥1,206,669,907.55 in Q1 2024[24] - The net cash flow from financing activities for Q1 2025 was ¥46,699,455.90, a decrease from ¥237,174,487.69 in Q1 2024[25] - The company reported a foreign exchange impact on cash and cash equivalents of -¥842,648.33 in Q1 2025, compared to a positive impact of ¥13,495,949.26 in Q1 2024[25] Operational Insights - Total operating costs for Q1 2025 were CNY 7,973,445,487.28, down 6.3% from CNY 8,513,876,388.41 in Q1 2024[20] - Gross profit margin for Q1 2025 improved to 15.0% from 12.5% in Q1 2024, indicating better cost management[20] - The company plans to focus on expanding its market presence and investing in new product development in the upcoming quarters[20] - Investment income for Q1 2025 reached ¥7,559,129.15, a significant increase from ¥3,651,674.19 in Q1 2024, representing a growth of approximately 106.5%[21]